How Many Ways Can a Podocyte Die?

Seminars in Nephrology

Volumn 32, Issue 4, 2012, Pages 394-404

  Tharaux, Pierre Louis ^a,b,c   Huber, Tobias B ^d,e  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Apoptosis; Autophagy; Necroptosis; Necrosis; Podocyte

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; ETANERCEPT; NEPHRIN; PODOCIN; PROTEIN P27; PROTEIN P57; TUMOR NECROSIS FACTOR ALPHA;

ANOIKIS; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL DEATH; CELL LOSS; CELL STRUCTURE; CELL SURVIVAL; CELL ULTRASTRUCTURE; DIABETIC NEPHROPATHY; FOCAL GLOMERULOSCLEROSIS; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION RATE; HIV ASSOCIATED NEPHROPATHY; HUMAN; MEMBRANOUS GLOMERULONEPHRITIS; MITOSIS INHIBITION; NECROPTOSIS; NECROSIS; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA;

ANIMALS; APOPTOSIS; AUTOPHAGY; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL PROLIFERATION; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; MITOCHONDRIA; NECROSIS; PODOCYTES; SIGNAL TRANSDUCTION;

EID: 84865703985     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.06.011     Document Type: Article

References (133)

1. Kim Y.H., Goyal M., Kurnit D., Wharram B., Wiggins J., Holzman L., et al. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 2001, 60:957-968.
2. Lemley K.V., Abdullah I., Myers B.D., Meyer T.W., Blouch K., Smith W.E., et al. Evolution of incipient nephropathy in type 2 diabetes mellitus. Kidney Int 2000, 58:1228-1237.
3. Lemley K.V., Lafayette R.A., Safai M., Derby G., Blouch K., Squarer A., et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002, 61:1475-1485.
4. Pagtalunan M.E., Miller P.L., Jumping-Eagle S., Nelson R.G., Myers B.D., Rennke H.G., et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997, 99:342-348.
5. Meyer T.W., Bennett P.H., Nelson R.G. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia 1999, 42:1341-1344.
6. White K.E., Bilous R.W., Marshall S.M., El Nahas M., Remuzzi G., Piras G., et al. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 2002, 51:3083-3089.
7. Gross M.L., El-Shakmak A., Szabo A., Koch A., Kuhlmann A., Munter K., et al. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003, 46:856-868.
8. Gross M.L., Ritz E., Schoof A., Helmke B., Parkman A., Tulp O., et al. Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker. Lab Invest 2003, 83:1267-1277.
9. Hara M., Yanagihara T., Takada T., Itoh M., Matsuno M., Yamamoto T., et al. Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis. Am J Nephrol 1998, 18:35-41.
10. Kihara I., Tsuchida S., Yaoita E., Yamamoto T., Hara M., Yanagihara T., et al. Podocyte detachment and epithelial cell reaction in focal segmental glomerulosclerosis with cellular variants. Kidney Int Suppl 1997, 63:S171-S176.
11. Hara M., Yanagihara T., Itoh M., Matsuno M., Kihara I. Immunohistochemical and urinary markers of podocyte injury. Pediatr Nephrol 1998, 12:43-48.
12. Ebihara I., Nakamura T., Ushiyama C., Suzuki S., Shimada N., Hara M., et al. Urinary podocytes in patients with chronic renal failure. Nephron 2000, 85:187.
13. Hara M., Yanagihara T., Kihara I. Urinary podocytes in primary focal segmental glomerulosclerosis. Nephron 2001, 89:342-347.
14. Nakamura T., Ushiyama C., Suzuki S., Hara M., Shimada N., Ebihara I., et al. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 2000, 15:1379-1383.
15. Nakamura T., Ushiyama C., Suzuki S., Hara M., Shimada N., Ebihara I., et al. The urinary podocyte as a marker for the differential diagnosis of idiopathic focal glomerulosclerosis and minimal-change nephrotic syndrome. Am J Nephrol 2000, 20:175-179.
16. Nakamura T., Ushiyama C., Suzuki S., Hara M., Shimada N., Sekizuka K., et al. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Am J Nephrol 2000, 20:373-379.
17. Nakamura T., Ushiyama C., Suzuki S., Hara M., Shimada N., Sekizuka K., et al. Urinary podocytes for the assessment of disease activity in lupus nephritis. Am J Med Sci 2000, 320:112-116.
18. Wharram B.L., Goyal M., Wiggins J.E., Sanden S.K., Hussain S., Filipiak W.E., et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005, 16:2941-2952.
19. Matsusaka T., Xin J., Niwa S., Kobayashi K., Akatsuka A., Hashizume H., et al. Genetic engineering of glomerular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol 2005, 16:1013-1023.
20. Matsusaka T., Sandgren E., Shintani A., Kon V., Pastan I., Fogo A.B., et al. Podocyte injury damages other podocytes. J Am Soc Nephrol 2011, 22:1275-1285.
21. Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972, 26:239-257.
22. Duprez L., Wirawan E., Vanden Berghe T., Vandenabeele P. Major cell death pathways at a glance. Microbes Infect 2009, 11:1050-1062.
23. Vandenabeele P., Galluzzi L., Vanden Berghe T., Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010, 11:700-714.
24. Galluzzi L., Vitale I., Abrams J.M., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012, 19:107-120.
25. Savill J. Apoptosis in disease. Eur J Clin Invest 1994, 24:715-723.
26. Otsuki Y., Li Z., Shibata M.A. Apoptotic detection methods-from morphology to gene. Prog Histochem Cytochem 2003, 38:275-339.
27. Muppidi J., Porter M., Siegel R.M. Measurement of apoptosis and other forms of cell death. Curr Protoc Immunol 2004, 17. Chapter 3.
28. Watanabe M., Hitomi M., van der Wee K., Rothenberg F., Fisher S.A., Zucker R., et al. The pros and cons of apoptosis assays for use in the study of cells, tissues, and organs. Microsc Microanal 2002, 8:375-391.
29. Sanderson C.J. The mechanism of T cell mediated cytotoxicity. II. Morphological studies of cell death by time-lapse microcinematography. Proc R Soc Lond B Biol Sci 1976, 192:241-255.
30. Matter A. Microcinematographic and electron microscopic analysis of target cell lysis induced by cytotoxic T lymphocytes. Immunology 1979, 36:179-190.
31. Evan G.I., Wyllie A.H., Gilbert C.S., Littlewood T.D., Land H., Brooks M., et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992, 69:119-128.
32. Krysko D.V., Vanden Berghe T., D'Herde K., Vandenabeele P. Apoptosis and necrosis: detection, discrimination and phagocytosis. Methods 2008, 44:205-221.
33. Bouchier-Hayes L., Munoz-Pinedo C., Connell S., Green D.R. Measuring apoptosis at the single cell level. Methods 2008, 44:222-228.
34. Loo D.T., Rillema J.R. Measurement of cell death. Methods Cell Biol 1998, 57:251-264.
35. Vogelmann S.U., Nelson W.J., Myers B.D., Lemley K.V. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 2003, 285:F40-F48.
36. Susztak K., Bottinger E.P. Diabetic nephropathy: a frontier for personalized medicine. J Am Soc Nephrol 2006, 17:361-367.
37. Schiffer M., Mundel P., Shaw A.S., Bottinger E.P. A novel role for the adaptor molecule CD2-associated protein in transforming growth factor-beta-induced apoptosis. J Biol Chem 2004, 279:37004-37012.
38. Schiffer M., Bitzer M., Roberts I.S., Kopp J.B., ten Dijke P., Mundel P., et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 2001, 108:807-816.
39. Jia J., Ding G., Zhu J., Chen C., Liang W., Franki N., et al. Angiotensin II infusion induces nephrin expression changes and podocyte apoptosis. Am J Nephrol 2008, 28:500-507.
40. Susztak K., Raff A.C., Schiffer M., Bottinger E.P. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006, 55:225-233.
41. van Roeyen C.R., Eitner F., Boor P., Moeller M.J., Raffetseder U., Hanssen L., et al. Induction of progressive glomerulonephritis by podocyte-specific overexpression of platelet-derived growth factor-D. Kidney Int 2011, 80:1292-1305.
42. Doublier S., Lupia E., Catanuto P., Periera-Simon S., Xia X., Korach K., et al. Testosterone and 17beta-estradiol have opposite effects on podocyte apoptosis that precedes glomerulosclerosis in female estrogen receptor knockout mice. Kidney Int 2011, 79:404-413.
43. Ryu M., Kulkarni O.P., Radomska E., Miosge N., Gross O., Anders H.J. Bacterial CpG-DNA accelerates Alport glomerulosclerosis by inducing an M1 macrophage phenotype and tumor necrosis factor-alpha-mediated podocyte loss. Kidney Int 2011, 79:189-198.
44. Ryu M., Mulay S.R., Miosge N., Gross O., Anders H.J. Tumour necrosis factor-alpha drives Alport glomerulosclerosis in mice by promoting podocyte apoptosis. J Pathol 2011, 226:120-131.
45. Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002, 296:1635-1636.
46. Peter M.E., Budd R.C., Desbarats J., Hedrick S.M., Hueber A.O., Newell M.K., et al. The CD95 receptor: apoptosis revisited. Cell 2007, 129:447-450.
47. Linkermann A., Bräsen J.H., Himmerkus N., Liu S., Huber T.B., Kunzendorf U., et al. RIP1-mediated necroptosis essentially contributes to renal ischemia/reperfusion injury. Kidney Int 2012, 81:751-761.
48. Bollee G., Flamant M., Schordan S., Fligny C., Rumpel E., Milon M., et al. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med 2011, 17:1242-1250.
49. Melk A., Kittikowit W., Sandhu I., Halloran K.M., Grimm P., Schmidt B.M., et al. Cell senescence in rat kidneys in vivo increases with growth and age despite lack of telomere shortening. Kidney Int 2003, 63:2134-2143.
50. Nagata M., Tomari S., Kanemoto K., Usui J., Lemley K.V. Podocytes, parietal cells, and glomerular pathology: the role of cell cycle proteins. Pediatr Nephrol 2003, 18:3-8.
51. Nagata M., Nakayama K., Terada Y., Hoshi S., Watanabe T. Cell cycle regulation and differentiation in the human podocyte lineage. Am J Pathol 1998, 153:1511-1520.
52. Bariety J., Hill G.S., Mandet C., Irinopoulou T., Jacquot C., Meyrier A., et al. Glomerular epithelial-mesenchymal transdifferentiation in pauci-immune crescentic glomerulonephritis. Nephrol Dial Transplant 2003, 18:1777-1784.
53. Griffin S.V., Krofft R.D., Pippin J.W., Shankland S.J. Limitation of podocyte proliferation improves renal function in experimental crescentic glomerulonephritis. Kidney Int 2005, 67:977-986.
54. Griffin S.V., Olivier J.P., Pippin J.W., Roberts J.M., Shankland S.J. Cyclin I protects podocytes from apoptosis. J Biol Chem 2006, 281:28048-28057.
55. Detwiler R.K., Falk R.J., Hogan S.L., Jennette J.C. Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis. Kidney Int 1994, 45:1416-1424.
56. Perry J., Ho M., Viero S., Zheng K., Jacobs R., Thorner P.S. The intermediate filament nestin is highly expressed in normal human podocytes and podocytes in glomerular disease. Pediatr Dev Pathol 2007, 10:369-382.
57. Bariety J., Bruneval P., Meyrier A., Mandet C., Hill G., Jacquot C. Podocyte involvement in human immune crescentic glomerulonephritis. Kidney Int 2005, 68:1109-1119.
58. Albaqumi M., Soos T.J., Barisoni L., Nelson P.J. Collapsing glomerulopathy. J Am Soc Nephrol 2006, 17:2854-2863.
59. Albaqumi M., Barisoni L. Current views on collapsing glomerulopathy. J Am Soc Nephrol 2008, 19:1276-1281.
60. Yang Y., Gubler M.C., Beaufils H. Dysregulation of podocyte phenotype in idiopathic collapsing glomerulopathy and HIV-associated nephropathy. Nephron 2002, 91:416-423.
61. Srivastava T., Garola R.E., Whiting J.M., Alon U.S. Cell-cycle regulatory proteins in podocyte cell in idiopathic nephrotic syndrome of childhood. Kidney Int 2003, 63:1374-1381.
62. Srivastava T., Garola R.E., Singh H.K. Cell-cycle regulatory proteins in the podocyte in collapsing glomerulopathy in children. Kidney Int 2006, 70:529-535.
63. Gherardi D., D'Agati V., Chu T.H., Barnett A., Gianella-Borradori A., Gelman I.H., et al. Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. J Am Soc Nephrol 2004, 15:1212-1222.
64. He J.C., Husain M., Sunamoto M., D'Agati V.D., Klotman M.E., Iyengar R., et al. Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways. J Clin Invest 2004, 114:643-651.
65. Korgaonkar S.N., Feng X., Ross M.D., Lu T.C., D'Agati V., Iyengar R., et al. HIV-1 upregulates VEGF in podocytes. J Am Soc Nephrol 2008, 19:877-883.
66. Feng X., Lu T.C., Chuang P.Y., Fang W., Ratnam K., Xiong H., et al. Reduction of Stat3 activity attenuates HIV-induced kidney injury. J Am Soc Nephrol 2009, 20:2138-2146.
67. Petermann A.T., Pippin J., Hiromura K., Monkawa T., Durvasula R., Couser W.G., et al. Mitotic cell cycle proteins increase in podocytes despite lack of proliferation. Kidney Int 2003, 63:113-122.
68. Husain M., Gusella G.L., Klotman M.E., Gelman I.H., Ross M.D., Schwartz E.J., et al. HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J Am Soc Nephrol 2002, 13:1806-1815.
69. Baker D.J., Chen J., van Deursen J.M. The mitotic checkpoint in cancer and aging: what have mice taught us?. Curr Opin Cell Biol 2005, 17:583-589.
70. Li M., Fang X., Baker D.J., Guo L., Gao X., Wei Z., et al. The ATM-p53 pathway suppresses aneuploidy-induced tumorigenesis. Proc Natl Acad Sci U S A 2010, 107:14188-14193.
71. Castedo M., Perfettini J.L., Roumier T., Yakushijin K., Horne D., Medema R., et al. The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 2004, 23:4353-4361.
72. Vakifahmetoglu H., Olsson M., Zhivotovsky B. Death through a tragedy: mitotic catastrophe. Cell Death Differ 2008, 15:1153-1162.
73. Vakifahmetoglu H., Olsson M., Tamm C., Heidari N., Orrenius S., Zhivotovsky B. DNA damage induces two distinct modes of cell death in ovarian carcinomas. Cell Death Differ 2008, 15:555-566.
74. Lasagni L., Ballerini L., Angelotti M.L., Parente E., Sagrinati C., Mazzinghi B., et al. Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders. Stem Cells 2010, 28:1674-1685.
75. Kriz W., Hahnel B., Rosener S., Elger M. Long-term treatment of rats with FGF-2 results in focal segmental glomerulosclerosis. Kidney Int 1995, 48:1435-1450.
76. Castedo M., Perfettini J.L., Roumier T., Kroemer G. Cyclin-dependent kinase-1: linking apoptosis to cell cycle and mitotic catastrophe. Cell Death Differ 2002, 9:1287-1293.
77. Vitale I., Galluzzi L., Castedo M., Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011, 12:385-392.
78. Brinkkoetter P.T., Olivier P., Wu J.S., Henderson S., Krofft R.D., Pippin J.W., et al. Cyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cells. J Clin Invest 2009, 119:3089-3101.
79. Simons M., Hartleben B., Huber T.B. Podocyte polarity signalling. Curr Opin Nephrol Hypertens 2009, 18:324-330.
80. Abe Y., Sakairi T., Kajiyama H., Shrivastav S., Beeson C., Kopp J.B. Bioenergetic characterization of mouse podocytes. Am J Physiol Cell Physiol 2010, 299:C464-C476.
81. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007, 87:99-163.
82. Hagiwara M., Yamagata K., Capaldi R.A., Koyama A. Mitochondrial dysfunction in focal segmental glomerulosclerosis of puromycin aminonucleoside nephrosis. Kidney Int 2006, 69:1146-1152.
83. Vandenabeele P., Vanden Berghe T., Festjens N. Caspase inhibitors promote alternative cell death pathways. Sci STKE 2006, 2006:pe44.
84. Jansen J.J., Maassen J.A., van der Woude F.J., Lemmink H.A., van den Ouweland J.M., t' Hart L.M., et al. Mutation in mitochondrial tRNA(Leu(UUR)) gene associated with progressive kidney disease. J Am Soc Nephrol 1997, 8:1118-1124.
85. Hotta O., Inoue C.N., Miyabayashi S., Furuta T., Takeuchi A., Taguma Y. Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene mutation. Kidney Int 2001, 59:1236-1243.
86. Diomedi-Camassei F., Di Giandomenico S., Santorelli F.M., Caridi G., Piemonte F., Montini G., et al. COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol 2007, 18:2773-2780.
87. Levine B., Klionsky D.J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004, 6:463-477.
88. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
89. Mehrpour M., Esclatine A., Beau I., Codogno P. Autophagy in health and disease. 1. Regulation and significance of autophagy: an overview. Am J Physiol Cell Physiol 2010, 298:C776-C785.
90. Wang Y., Martinez-Vicente M., Kruger U., Kaushik S., Wong E., Mandelkow E.M., et al. Synergy and antagonism of macroautophagy and chaperone-mediated autophagy in a cell model of pathological tau aggregation. Autophagy 2010, 6:182-183.
91. Asanuma K., Tanida I., Shirato I., Ueno T., Takahara H., Nishitani T., et al. MAP-LC3, a promising autophagosomal marker, is processed during the differentiation and recovery of podocytes from PAN nephrosis. FASEB J 2003, 17:1165-1167.
92. Hartleben B., Godel M., Meyer-Schwesinger C., Liu S., Ulrich T., Kobler S., et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest 2010, 120:1084-1096.
93. Debnath J., Baehrecke E.H., Kroemer G. Does autophagy contribute to cell death?. Autophagy 2005, 1:66-74.
94. Levine B., Yuan J. Autophagy in cell death: an innocent convict?. J Clin Invest 2005, 115:2679-2688.
95. Boya P., Gonzalez-Polo R.A., Casares N., Perfettini J.L., Dessen P., Larochette N., et al. Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 2005, 25:1025-1040.
96. Pattingre S., Tassa A., Qu X., Garuti R., Liang X.H., Mizushima N., et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005, 122:927-939.
97. Yu L., Alva A., Su H., Dutt P., Freundt E., Welsh S., et al. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science 2004, 304:1500-1502.
98. Yu L., Wan F., Dutta S., Welsh S., Liu Z., Freundt E., et al. Autophagic programmed cell death by selective catalase degradation. Proc Natl Acad Sci U S A 2006, 103:4952-4957.
99. Bonapace L., Bornhauser B.C., Schmitz M., Cario G., Ziegler U., Niggli F.K., et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest 2010, 120:1310-1323.
100. Kang R., Tang D., Lotze M.T., Zeh H.J. RAGE regulates autophagy and apoptosis following oxidative injury. Autophagy 2011, 7:442-444.
101. Ding Y., Kim J.K., Kim S.I., Na H.J., Jun S.Y., Lee S.J., et al. TGF-{beta}1 protects against mesangial cell apoptosis via induction of autophagy. J Biol Chem 2010, 285:37909-37919.
102. Niranjan T., Bielesz B., Gruenwald A., Ponda M.P., Kopp J.B., Thomas D.B., et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med 2008, 14:290-298.
103. Yadav A., Vallabu S., Arora S., Tandon P., Slahan D., Teichberg S., et al. ANG II promotes autophagy in podocytes. Am J Physiol Cell Physiol 2010, 299:C488-C496.
104. Liebau M.C., Lang D., Bohm J., Endlich N., Bek M.J., Witherden I., et al. Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol 2006, 290:F710-F719.
105. Wang L., Chang J.H., Paik S.Y., Tang Y., Eisner W., Spurney R.F. Calcineurin (CN) activation promotes apoptosis of glomerular podocytes both in vitro and in vivo. Mol Endocrinol 2011, 25:1376-1386.
106. Zhang H., Ding J., Fan Q., Liu S. TRPC6 up-regulation in Ang II-induced podocyte apoptosis might result from ERK activation and NF-kappaB translocation. Exp Biol Med (Maywood) 2009, 234:1029-1036.
107. Eckel J., Lavin P.J., Finch E.A., Mukerji N., Burch J., Gbadegesin R., et al. TRPC6 enhances angiotensin II-induced albuminuria. J Am Soc Nephrol 2011, 22:526-535.
108. Winn M.P., Conlon P.J., Lynn K.L., Farrington M.K., Creazzo T., Hawkins A.F., et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005, 308:1801-1804.
109. Fukuda A., Wickman L.T., Venkatareddy M.P., Sato Y., Chowdhury M.A., Wang S.Q., et al. Angiotensin II-dependent persistent podocyte loss from destabilized glomeruli causes progression of end stage kidney disease. Kidney Int 2012, 81:40-55.
110. Racusen L.C., Prozialeck D.H., Solez K. Glomerular epithelial cell changes after ischemia or dehydration. Possible role of angiotensin II. Am J Pathol 1984, 114:157-163.
111. Harrison-Bernard L.M., Navar L.G., Ho M.M., Vinson G.P., el-Dahr S.S. Immunohistochemical localization of ANG II AT1 receptor in adult rat kidney using a monoclonal antibody. Am J Physiol 1997, 273:F170-F177.
112. Crowley S.D., Vasievich M.P., Ruiz P., Gould S.K., Parsons K.K., Pazmino A.K., et al. Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest 2009, 119:943-953.
113. Rebibou J.M., He C.J., Delarue F., Peraldi M.N., Adida C., Rondeau E., et al. Functional endothelin 1 receptors on human glomerular podocytes and mesangial cells. Nephrol Dial Transplant 1992, 7:288-292.
114. Fligny C., Barton M., Tharaux P.L. Endothelin and podocyte injury in chronic kidney disease. Contrib Nephrol 2011, 172:120-138.
115. Flannery P.J., Spurney R.F. Transactivation of the epidermal growth factor receptor by angiotensin II in glomerular podocytes. Nephron Exp Nephrol 2006, 103:e109-e118.
116. Daub H., Weiss F.U., Wallasch C., Ullrich A. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996, 379:557-560.
117. Chansel D., Ciroldi M., Vandermeersch S., Jackson L.F., Gomez A.M., Henrion D., et al. Heparin binding EGF is necessary for vasospastic response to endothelin. FASEB J 2006, 20:1936-1938.
118. Furuta S., Hidaka E., Ogata A., Yokota S., Kamata T. Ras is involved in the negative control of autophagy through the class I PI3-kinase. Oncogene 2004, 23:3898-3904.
119. Conde E., Angulo B., Tang M., Morente M., Torres-Lanzas J., Lopez-Encuentra A., et al. Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res 2006, 12:710-717.
120. Chiu T., Santiskulvong C., Rozengurt E. EGF receptor transactivation mediates ANG II-stimulated mitogenesis in intestinal epithelial cells through the PI3-kinase/Akt/mTOR/p70S6K1 signaling pathway. Am J Physiol Gastrointest Liver Physiol 2005, 288:G182-G194.
121. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
122. Castedo M., Ferri K.F., Kroemer G. Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ 2002, 9:99-100.
123. Welsh G.I., Hale L.J., Eremina V., Jeansson M., Maezawa Y., Lennon R., et al. Insulin signaling to the glomerular podocyte is critical for normal kidney function. Cell Metab 2010, 12:329-340.
124. Han W., Pan H., Chen Y., Sun J., Wang Y., Li J., et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One 2011, 6:e18691.
125. Xu S., Weihua Z. Loss of EGFR induced autophagy sensitizes hormone refractory prostate cancer cells to adriamycin. Prostate 2011, 71:1216-1224.
126. Li X., Lu Y., Pan T., Fan Z. Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. Autophagy 2010, 6:1066-1077.
127. Yan J., Yang H., Wang G., Sun L., Zhou Y., Guo Y., et al. Autophagy augmented by troglitazone is independent of EGFR transactivation and correlated with AMP-activated protein kinase signaling. Autophagy 2010, 6:67-73.
128. Ravikumar B., Berger Z., Vacher C., O'Kane C.J., Rubinsztein D.C. Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet 2006, 15:1209-1216.
129. Sakairi T., Abe Y., Kajiyama H., Bartlett L.D., Howard L.V., Jat P.S., et al. Conditionally immortalized human podocyte cell lines established from urine. Am J Physiol Renal Physiol 2010, 298:F557-F567.
130. Frisch S.M., Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994, 124:619-626.
131. Cardone M.H., Salvesen G.S., Widmann C., Johnson G., Frisch S.M. The regulation of anoikis: MEKK-1 activation requires cleavage by caspases. Cell 1997, 90:315-323.
132. Reginato M.J., Mills K.R., Paulus J.K., Lynch D.K., Sgroi D.C., Debnath J., et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 2003, 5:733-740.
133. Bruggeman L.A., Drawz P.E., Kahoud N., Lin K., Barisoni L., Nelson P.J. TNFR2 interposes the proliferative and NF-kappaB-mediated inflammatory response by podocytes to TNF-alpha. Lab Invest 2011, 91:413-425.